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Abstract 
Objective: This study aims to determine if the prognostic significance of troponins in acute 
coronary syndrome in predicting mortality varies by age, and if so, to what extent when other 
prognostic indicators are considered. 
Methods: We analysed Myocardial Ischemia National Audit Project registry data collected 
between January 2006 and December 2010 and followed up this cohort for all-cause 
mortality until August 2011. Relationships between peak troponin levels (types I and T) and 
time to death in different age groups, and between age and time to death at different troponin 
levels were investigated using multiple variable adjusted Cox regression models.   
Results: Of the 322,617 patients with acute coronary syndromes included, a third 
(n=106,365, 33%) died during 695,334 person-years of follow-up. Within each troponin 
category, older age was associated with a higher mortality even in those with a troponin 
<0.01 ng/ml for both troponin types (HR ~10-12 in ≥85 years cf. HR of 1.0 in <65 years). 
The relative potency of an elevated troponin to predict an adverse outcome compared to a 
low troponin attenuated with increased age (for troponin I ≥15.0 compared to troponin I 
<0.01 in age <65, adjusted HR 2.41 (95% confidence interval (CI) 1.80-3.24); age ≥85 HR 
2.01 (1.62-2.52)). Similar but less consistent results were observed with troponin T elevation 
at the higher levels. 
Conclusion: Clinicians should interpret the prognostic value of troponin taking into account 
the patient’s age.  
 Key questions 
What is already known about the subject? 
 The prognostic significance of cardiac troponin is well documented but little research 
has focused on whether this varies with age. 
What does this study add? 
 We found the risk of mortality in older patients were very high compared to the 
younger patients even among patients with the lowest troponin levels. 
 The magnitude of risk of mortality with similarly high troponin levels tended to 
decrease in older age group compared to younger age group. 
How might this impact clinical practice? 
 Clinicians should interpret the prognostic value of troponins taking into account of the 
patient’s age.  
Introduction  
 Cardiac troponins are both sensitive and specific markers of myocardial cell damage 
and have prognostic significance in acute coronary syndrome, with higher levels predicting 
worse outcomes.[1,2] Recent evidence suggests that  levels of troponin I as low as 0.012-
0.049 ng/ml carry a significant risk of recurrent myocardial infarction or death compared to a 
troponin I level of <0.012.[3] However, it is not known whether troponins have equal or more 
or less prognostic value in patients  aged 65-84 years compared to those who are  older (85+ 
years) and those who are younger(<65 years years).  
 
 Understanding the prognostic significance of troponins in older patients is important 
as there is a rapidly ageing population in developed world societies yet most clinical trials 
exclude patients with very old age.  Acute coronary syndrome (ACS) is also more prevalent 
in older age and recent work by our group[4,5] and others[3] suggest that even a minimal rise 
in troponin may be associated with worse outcomes in older patients. Therefore it is likely 
that a troponin rise in older age may have a different prognostic value compared to those who 
are younger and may vary even within the older age spectrum.  
 
 Therefore, we aimed to address two related research questions: (1) does the 
prognostic significance of troponins in ACS in predicting mortality vary by age, and if so, (2) 
to what extent, when other prognostic indicators such as age, sex, co-morbidities, treatment 
receipt and site and level of care are also considered? 
 Methods 
Study design and population 
 This was a cohort study of all patients aged 18 years or over in the United Kingdom 
Myocardial Ischemia National Audit Project (MINAP) database admitted to all 230 NHS 
hospital trusts in England and Wales between January 2006 and December 2010 who had a 
confirmed diagnosis of an acute coronary syndrome. For the purposes of this study, eligibility 
criteria were defined as any ACS as determined by the medical teams at time of discharge, 
including ST-segment elevation myocardial infarction (STEMI) and other acute coronary 
syndromes (non-ST elevation myocardial infarction (Non-STEMI), troponin negative ACS, 
threatened and unconfirmed myocardial infarction). The outcome was all-cause mortality 
outcome at follow up of up to August 2011. We deliberately excluded entries to MINAP prior 
to 2006 as the use of primary percutaneous coronary intervention in the UK was less than 
10% before 2006.[6] Mortality was ascertained through linkage with the Office of National 
Statistics.[7] 
 
Data collection 
 The MINAP dataset is contributed to by all 230 NHS trusts in England and Wales and 
uses a standardised data format that allows examination of pre-hospital and in-hospital care 
of all acute coronary syndromes, and is a part of the NHS data dictionary.[8] The 
development and initial findings of MINAP have been previously reported.[9,10] The dataset 
was collected by nurses and clinical audit staff and contains 123 fields.[11]  The subset of 
variables included and description of variables are described in Data Supplement 1. We used 
the cut offs of <65 year, 65-74 years, 75-84 years and ≥85 years as age groups.  Furthermore, 
we defined participants who were <65 years as young, participants who were 65-74 years as 
younger elderly, 75-84 years as older elderly and ≥85 as oldest old. 
 Statistical methods 
 We investigated associations between troponin levels, age group and other prognostic 
variables using Spearman correlation test for continuous variables, Cuzick non-parametric 
test for trend for binary variables and chi square test for other categorical variables. We 
estimated the independent effects of prognostic variables on time to death using Cox 
proportional hazards models. To assess the proportionality of hazards between age or 
troponin subgroups, postestimation complementary log log plots were constructed. These 
produced parallel lines for the different subgroups, confirming that hazards were proportional 
for the primary explanatory variables. Statistical tests of proportional hazards could be 
misleading, given the very large sample.  All analyses were performed using Stata statistical 
software (Version 10.1, StatCorp, USA).   
 
Missing values of variables other than troponin measurements were imputed using multiple 
imputation by chained equation method in STATA, assuming that data were missing at 
random.[12.13]  In fact, previous imputation analyses on the MINAP dataset[14] have not 
significantly altered effect sizes and imply that missing data in MINAP is at random whilst 
work by others has also shown that the level of missing data  does not alter regional 
standardised mortality ratios.[15] 
 
 Troponin I and T levels were used in the imputations, but for the statistical analyses 
patients with missing troponin levels were excluded from the respective analyses. We 
analysed 10 imputed datasets, with point estimates and standard errors calculated using 
Rubin's rules.[16]
 
Analysis of baseline characteristics of participants was restricted to the 
complete data only but the Cox regression analyses presented results of the imputed data.
  
 
  Analysis was stratified by the type of troponin measured (I and T) and age group 
(<65, 65-74, 75-84 and ≥85 years).  For each troponin type, we re-categorised six categories 
(troponin specific) based on pre-specified cut off points. The cut off points for troponin I 
were <0.01, 0.01-0.049, 0.05-0.49, 0.5-2.49, 2.5-14.99 and ≥15.0. For troponin T the cut off 
points were <0.01, 0.01-0.049, 0.05-0.099, 0.1-0.49, 0.5-1.79 and ≥1.8).  These cut off points 
represent respective percentile values equivalent to each other; the troponin I cut off points 
were predetermined first based on clinically meaningful cut off points at lower levels and 
then 25
th
, 50
th
 and 75
th
 centile values and the equivalent troponin T values were determined 
based on similar percentile values.  
 
 The explanatory variables in the Cox models were  troponin I or T levels, age group, 
sex, BMI, current smokers, family history of heart disease, STEMI or non-STEMI (any ACS 
other than STEMI as defined in this study), co-morbidities (hypertension, diabetes, MI, 
angina, stroke, heart failure, chronic renal failure, peripheral vascular disease), previous PCI, 
previous CABG, serum cholesterol, serum glucose, troponin group, medications prior to 
admission (aspirin, ACEi, beta-blocker, statin, clopidogrel), speciality of consultant in charge 
at the time of admission and admission ward.  All of these variables were independently 
associated with time to death in the full models. We adjusted for medications that patients 
had been taking on admission because there were potential confounders that could affect 
survival.  However, we did not include in the multivariate model medications that were 
started after the admission because there could have been a causal relationship between 
admission and subsequent death or survival.  
 
 We additionally tested whether age modified the effect of troponin and vice versa by 
adding age-troponin interaction variables to the Cox models, assessing statistical significance 
using Wald chi-squared tests. Hazard ratios for troponin within each age stratum and for age 
within each troponin stratum were estimated using linear combinations of terms after each 
regression.  
Results 
 A total of 424,848 patient records were available in the MINAP registry over 5 years 
(2006-2010).  After exclusion of patients with missing troponin and mortality data and those 
with a final diagnosis of non-ACS chest pain (e.g. pericarditis), the study cohort consisted of 
322,617 participants.  Peak troponin I and T were measured in 186,988 participants and 
135,629 participants respectively. The mean age of the entire cohort was 70.0 (SD14.0) years 
and 208,343 participants (65%) were men. The mean follow up was just over 2.0 years 
(789±564 days; 695,334 person-years; median follow up 706 days (inter quartile range 308-
1227 days).   
 
 The characteristics of the study sample by peak troponin specific group stratified by 
different age groups are shown in Table 1. There were a decreasing proportion of men, 
current smokers and participants with a positive family history of heart disease with older age 
groups.  In all age groups, the most common known co-morbidities were hypertension and 
hyperlipidaemia, the former more common with older age, the latter less common.  Older age 
was significantly associated with prevalence of prior cardiovascular disease and chronic renal 
failure. Prior PCI was most prevalent in participants from the youngest age group whilst prior 
CABG was most prevalent in those aged 65-84 years.  With regards to peak troponin levels, 
lower levels of peak troponins were observed with older age.  Except for aspirin, all other 
cardiac medication specific to ACS were used significantly less frequently in older age 
groups. Younger patients were more likely to be treated by a cardiologist and admitted to a 
coronary care unit. The proportion of patients with a confirmed diagnosis of STEMI 
decreased with age.  The characteristics of the study sample stratified by peak troponin 
categories are shown in Supplementary Table 1.  A total of 106,365 patients (33%) died 
during the follow-up. The crude mortality of oldest old (≥85 years) was very high compared 
to those <65 years; >60% vs. 7-8% during the overall follow-up (Supplementary Figure 1). 
Mortality at 1-year were 44.5% and 4.6%, respectively. Comparing this to expected mortality 
of the same age categories of general population in the UK (data source: Office of National 
Statistics. Death registration by single year of age 
http://www.ons.gov.uk/ons/rel/vsob1/death-registrations-by-single-year-of-age/united-
kingdom-2011/index.html) confirms the disproportionate incremental increase with older age 
(see Supplementary Figure 2).  
 
 The hazard ratios for mortality in older age groups compared to the youngest age 
group, stratified by troponins levels, are shown in Table 2 and Figure 1. Within each troponin 
category, older age was associated with a higher mortality and whilst adjusting for all 
potential confounders attenuated the higher risk of death with increased age, the results 
remained highly significant statistically. Even in the lowest category level of troponins I and 
T (<0.01 ng/ml), older patients had very high mortality compared to younger patients (HRs 
for oldest old age group (≥85 years) compared to young age group (<65 years; reference 
hazard ratio of 1.00) showed adjusted HRs 11.70 and 9.24 respectively for troponin I and T). 
The age-troponin interaction term was statistically significant for both troponin I and troponin 
T models (P<0.0001).  
 
 The hazards ratios of mortality associated with troponin levels stratified by age are 
shown in Table 3 and Figure 2. Higher troponin levels were associated with increasing risk of 
mortality in all age groups. However, the relative potency of an elevated troponin to predict 
an adverse outcome compared to a low troponin attenuated with increased age (for troponin I 
≥15.0 compared to troponin I <0.01 in age <65, adjusted HR 2.41 (95% confidence interval 
(CI) 1.80-3.24); age ≥85 HR 2.01 (1.62-2.52)). A similar attenuation was observed for 
troponin T up to troponin levels of 0.1; however at levels higher than 0.1, the relative potency 
of troponin to predict an adverse outcome did not attenuate with increased age.  
 
Secondary sensitivity analyses by additionally adjusting for discharge medications and 
reperfusion strategies in the model did not alter the results (data not shown).
Discussion 
 Our results showed that in any age group, higher troponin levels were associated with 
increasing risk of mortality. We found very high mortality rates in older patients even at the 
lowest troponin values. There was an attenuation of the prognostic value of troponins in older 
age. Thus, the prognostic value of troponins depends on patient age in acute coronary 
syndrome.  
 
 The very high mortality rates in older patients even at the lowest troponin values 
usually regarded as normal (<0.04) may be partly explained by frailty and other unknown 
confounders; there may also be differences in care delivered for older patients with ACS as 
with increasing age, we found cardiac medication specific to ACS were used significantly 
less frequently in older age groups. Our observations show that older patients are less likely 
to be managed by cardiologists, less likely to be managed in coronary care units, intensive 
care units and cardiac wards.  Other studies have also found that older patients were more 
likely to receive medical treatments[17] and are less likely to receive evidence-based 
treatments, including myocardial revascularisation therapy.[18]  Therefore, the higher 
mortality we report in the older patient with ACS might be associated with poor physiological 
reserve, frailty and increased co-morbidity but equally may be driven by lesser receipt of 
evidence-based treatments and the fact they tend to be managed with a more conservative 
strategy compared to younger patients.
  
 
 Due to  uncertainties around the benefits of the invasive interventions,  despite their 
higher risk of adverse clinical outcomes following ACS, older patients may often be managed 
with more conservative strategies compared to younger patients.[19] Although, there is 
evidence to suggest that adherence to guideline-recommended therapy is associated with a 
decrease in mortality, [20]   the management of ACS in older age is challenging.  It is well 
documented that older patients are more likely to present atypically (e.g. with dyspnoea 
rather than chest pain) compared to younger patients with ACS[21]  and it has been suggested 
that there are  high misdiagnosis rates and inappropriate discharge rates for ACS particularly 
in older populations.[22,23].   Our study is limited to those who were entered into the 
MINAP registry and this might have introduced some selection bias and thus the estimated 
hazard risks in the oldest old might have been underestimated.  
 
 We found interestingly that even with the lowest troponin levels in ACS, the risk of 
death in older patients was very high (even higher than the other troponin groups) compared 
to younger counterparts. The exact reason for this is unclear. A recent cohort study suggests 
that lowering the troponin I threshold using the lowest percentile as cut off point would 
identify more patients with acute coronary syndrome who are at risk of recurrent myocardial 
infarction and death.[3] It is possible that patients with lowest troponin had myocardial 
damage but because the peak troponin value was not very high they were not adequately 
investigated and treated. However, we adjusted for a large number of potential confounders.  
 We have previously found that “incidental rises in troponin” in older patients in the 
absence of evidence of ACS (STEMI or NSTEMI) and any other known causes of troponin 
elevation predicted outcomes comparable to those of someone having had an ACS.[5] We 
postulated that the minimal rise in cardiac troponins in such circumstances may be related to 
myocardial necrosis and perhaps served as a prognostic marker indicating cardiac frailty in 
older patients with general illness other than an ACS. Studies suggest that even mild transient 
elevations of troponin levels are associated with increased mortality and major cardiovascular 
events in the general population.[24,25] It has been suggested that microvascular coronary 
artery disease in congestive heart failure, diabetes and chronic kidney disease may cause 
troponin elevations.  In heart failure, left ventricular strain, decreased subendothelial  
perfusion, endothelial dysfunction and apoptosis may cause troponin rises and microvascular 
disease are known to occur in diabetes and chronic kidney disease.[25]  In addition, older 
people may not have as high a troponin rise as in younger people despite having a similar 
extent of cardiac damage because age related physiological changes in cardiac myocytes may 
influence the response to injury.   
 
 For the first time, we report the attenuation of the prognostic value of troponins in 
older age.  It is possible that this attenuation may be apparent due to very high baseline risk in 
older patients even in the troponin values which fell within normal reference range. The other 
plausible reason behind this is that with increasing age, the global risk factor profile worsens 
and thus these competing risks may attenuate the prognostic significance of troponins in older 
age. Clinicians should be aware that troponin values in isolation do not provide the whole 
prognostic outlook of the patient. 
    
 Our study has several strengths.  First, we analysed a large sample which captures 
sufficient variations of patients in all ages and troponin levels. As the MINAP data is based 
on all NHS trusts in England and Wales, the findings are representative of UK and Western 
populations in general. Secondly, we were able to adjust for individual prognostic factors and 
a variety of potential confounding factors which may affect mortality outcome. We were also 
able to consider both troponins I and T separately, and have shown similar results in both 
allowing us more confidence in the validity of these findings. Furthermore, we included 
patients since 2006 only to allow comparison to contemporary standards of management of 
ACS.  
 
Study limitations 
 Our study has some limitations.  First, most patients had some prognostic data 
missing, which we replaced using multiple imputation and meant we were unable to 
undertake a complete dataset analysis. The primary outcome was all-cause mortality and we 
were unable to determine if the cause of death was related to a cardiac pathology. Although 
we have adjusted for several potential confounders, there remains the possibility of residual 
confounding.  Whilst we were able to take into account whether the initial care was delivered 
by a cardiologist or non-cardiologist, we could not establish if the subsequent care may have 
involved a cardiologist.  One other limitation was that we did not have information on 
reperfusion therapy for patients.  However, previously analyses within MINAP have reported 
that receipt of evidence-based cardiac medications post ACS is less in older age groups,  [26] 
and we expect that our cohort will be similar to other cohorts in literature where it has been 
reported that younger patients are more likely to receive reperfusion therapy [27].  Another 
limitation was that we do not have information on time to therapy as we expect that delay in 
presentation may be associated with delayed treatment and worse outcomes. However chest 
pain in older person is usually associated with a heart attack compared to a younger person 
and we have no reason to believe age would have influenced the health seeking behaviour 
particularly with regard to chest pain. 
 
Future studies 
 Future studies should evaluate the prognostic value of re-defining the cut off points 
for troponins based on the patient’s age.  Furthermore, randomised trials should examine 
whether targeted assessments and interventions would improve the outcome in patients in 
older age with ACS including those with minimal troponin rise regardless of the clinical 
diagnosis.  These future randomised studies should also consider the feasibility, clinical and 
cost effectiveness of individually tailored specialised management of ACS in older age, who 
currently remain at high risk following ACS but have concomitantly less specialist cardiology 
input.  
 
Conclusions 
 In conclusion, we have shown that the prognostic significance of troponin in ACS 
attenuates with increased age and that older age is associated with a worse prognosis 
compared to younger counterparts given the same level of troponin rise, even at very low 
levels of troponin.  Therefore, the age of the patient should be taken into consideration when 
assessing the prognosis of a patient given a raised troponin value for prognostication in ACS 
based on this evidence.   
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Table and Figure legends 
Table 1: Troponin assay specific baseline characteristics of 322,617 men and women of the 
MINAP acute coronary syndrome cohort (2006-2011) according to age category by different 
troponin assays  
Table 2: Troponin specific unadjusted and adjusted hazards ratios and their corresponding 
95% confidence intervals for the risk of mortality for people in the older age groups 
compared to the people in the youngest age group (<65 years) within troponin strata 
Table 3: Unadjusted and adjusted hazards ratios and their corresponding 95% confidence 
intervals for mortality for higher troponin level categories compared to the lowest level of 
troponin (<0.01 ng/ml) within the same age strata 
 
Supplementary Table 1: Troponin assay specific baseline characteristics of 322,617 men 
and women of the MINAP acute coronary syndrome cohort (2006-2011) according to 
different troponin categories 
 
Supplementary Table 2: Comparison of baseline characteristics of the included and 
excluded cohort 
 
Figure 1: Adjusted hazards ratios (95% confidence intervals) of mortality according to 
various age groups within troponin strata 
 
Figure 2: Adjusted hazard ratios (95% confidence intervals) of mortality according to various 
levels of peak troponin categories within age strata 
 
Supplementary Figure 1: Crude mortality rates (95% confidence intervals) at follow up 
(August 2011) in different age groups by peak troponin categories 
Supplementary Figure 2: Crude mortality rates (95% confidence intervals) compared to 
expected mortality of similar age categories at follow up (August 2011) for the oldest and 
youngest age groups by peak troponin categories  
 
Data Supplement 1: MINAP description of variables in analysis and definitions of variables 
 
Table 1: Troponin assay specific baseline characteristics of 322,617 men and women of the MINAP acute coronary syndrome cohort 
(2006-2011) according to age category by different troponin assays  
 
Variable* Troponin I cohort (n=186,988) Troponin T cohort (n=135,629) 
Age group (years) <65 
(n=65,761) 
65-74 
(n=44,564) 
75-84 
(n=49,611) 
≥85 
(n=27,052) 
P 
value‡ 
<65 
(n=47,123) 
65-74 
(n=31,527) 
75-84 
(n=36,163) 
≥85 
(n=20,816) 
P-value† 
Men 51,292 (78) 29,831 (67) 27,762 (56) 11,576 (43) <0.0001 36,984 (79) 21,272 (68) 20,475 (57) 9,151 (44) <0.0001 
BMI (kg/m
2
) 29 (6) 28 (6) 26 (5) 24 (5) <0.0001 29 (6) 28 (5) 26 (5) 25 (5) <0.0001 
Current smokers 29,413 (47) 9,362 (22) 5,134 (11) 1,191 (5) <0.0001 22,359 (49) 7,125 (24) 4,027 (12) 977 (5) <0.0001 
IMD score 23 (16) 21 (15) 20 (15) 19 (14) <0.0001 27 (17) 25 (17) 23 (16) 22 (15) <0.0001 
Family history of 
heart disease 
26,881 (47) 11,499 (32) 7,945 (21) 2,218 (11) <0.0001 19,105 (49) 8,216 (35) 6,087 (24) 1,915 (15) <0.0001 
Prior co-morbidities 
Hyperlipidemia 23,196 (37) 17,366 (41) 16,805 (36) 6,231 (25) <0.0001 15,022 (35) 11,501 (40) 11,593 (35) 4,822 (26) <0.0001 
Hypertension 26,122 (41) 23,823 (55) 28,673 (60) 14,763 (57) <0.0001 17,792 (40) 16,029 (54) 20,214 (59) 11,138 (57) <0.0001 
Diabetes 10,444 (16) 10,908 (25) 12,119 (25) 4,629 (18) <0.0001 7,054 (15) 7,603 (25) 8,510 (24) 3,556 (18) <0.0001 
MI 12,631 (20) 12,916 (30) 16,876 (35) 9,284 (35) <0.0001 8,331 (19) 8,413 (28) 11,781 (34) 6,842 (35) <0.0001 
Angina 13,149 (21) 14,803 (35) 19,868 (42) 11,090 (43) <0.0001 9,422 (21) 10,103 (34) 14,382 (42) 8,570 (44) <0.0001 
Heart failure 1,116 (2) 2,160 (5) 4,327 (9) 3,463 (13) <0.0001 849 (2) 1,600 (5) 3,289 (10) 2,679 (14) <0.0001 
Stroke 2,235 (4) 3,860 (9) 6,149 (13) 3,823 (15) <0.0001 1,645 (4) 2,738 (9) 4,567 (14) 3,025 (16) <0.0001 
Chronic renal failure 1,262 (2) 2,155 (5) 4,140 (9) 2,742 (11) <0.0001 1,000 (2) 1,515 (5) 2,911 (9) 1,999 (10) <0.0001 
PVD 1,756 (3) 2,378 (6) 2,874 (6) 1,207 (5) <0.0001 1,319 (3) 1,755 (6) 2,334 (7) 994 (5) <0.0001 
Prior interventions 
PCI 7,530 (12) 5,671 (13) 4,666 (10) 1,088 (4) <0.0001 5,042 (12) 3,585 (12) 3,012 (9) 729 (4) <0.0001 
CABG 2,926 (5) 4,456 (10) 4,588 (10) 948 (4) <0.0001 1,892 (4) 2,922 (10) 3,124 (9) 712 (4) <0.0001 
Biochemical results 
Troponin (ng/ml) 16.8 (27.3) 14.1 (24.5) 12.7 (23.1) 11.8 (21.9) <0.0001 3.11 (13.23) 2.91 (13.26) 2.77 (12.64) 2.79 (14.10) <0.0001 
Cholesterol (mmol/L) 5.2 (1.6) 4.6 (1.5) 4.3 (1.5) 4.2 (1.6) <0.0001 5.2 (1.6) 4.6 (1.6) 4.3 (1.6) 4.1 (1.7) <0.0001 
Glucose (mmol/L) 7.9 (4.6) 8.4 (4.7) 8.5 (4.6) 8.4 (4.5) <0.0001 8.1 (5.4) 8.6 (5.5) 8.7 (5.4) 8.4 (4.6) <0.0001 
Admission medications 
ACE inhibitor 17,689 (30) 16,642 (42) 20,199 (46) 10,098 (41) <0.0001 12,550 (30) 11,517 (41) 14,619 (45) 7,734 (41) <0.0001 
Beta blocker 14,745 (25) 13,331 (34) 16,107 (36) 8,350 (34) <0.0001 10,760 (26) 9,142 (33) 11,644 (36) 6,557 (35) <0.0001 
Statin 21,869 (36) 20,911 (52) 24,429 (54) 10,940 (44) <0.0001 15,875 (37) 14,711 (51) 17,801 (54) 8,452 (44) <0.0001 
Clopidogrel 5,279 (15) 4,365 (19) 4,997 (19) 2,446 (18) <0.0001 5,020 (18) 3,698 (20) 4,565 (21) 2,419 (20) <0.0001 
Aspirin 36,256 (55) 26,241 (59) 28,556 (58) 14,674 (54) 0.414 26,282 (56) 18,607 (59) 20,973 (58) 11,568 (56) 0.109 
Management, setting and diagnosis 
Cardiologist as lead 
consultant 
34,088 (53) 20,480 (47) 18,570 (38) 7,086 (27) <0.0001 26,091 (56) 15,557 (50) 14,899 (42) 6,767 (33) <0.0001 
Admission ward 
CCU 
ITU 
Cardiac ward 
Other 
 
36,448 (60) 
959 (2) 
5,544 (9) 
19,262 (31) 
 
21,426 (51) 
775 (2) 
3,979 (9) 
15,773 (38) 
 
19,830 (43) 
636 (1) 
4,254 (9) 
21,150 (46) 
 
8,373 (34) 
150 (1) 
2,038 (8) 
13,748 (57) 
 
<0.0001 
 
30,521 (67) 
778 (2) 
2,948 (7) 
11,102 (24) 
 
17,932 (60) 
538 (2) 
2,236 (8) 
9,077 (30) 
 
17,474 (53) 
487 (1) 
2,505 (8) 
12,626 (38) 
 
7,872 (43) 
119 (1) 
1,384 (8) 
8,763 (48) 
 
<0.0001 
 
Diagnosis 
STEMI 
ACS but not STEMI 
 
27,022 (41) 
38,739 (59) 
 
13,706 (31) 
30,858 (69) 
 
11,972 (24) 
37,639 (76) 
 
5,328 (20) 
21,724 (80) 
 
<0.0001 
 
22,054 (47) 
25,069 (53) 
 
11,361 (36) 
20,166 (64) 
 
10,206 (28) 
25,957 (72) 
 
4,716 (23) 
16,100 (77) 
 
<0.0001 
Outcome 
Death at follow up 4,398 (7) 8,793 (20) 18,991 (38) 16,181 (60) <0.0001 3,593 (8) 6,818 (22) 15,394 (43) 13,367 (64) <0.0001 
 
* Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  † Spearman correlation test for continuous variables, 
Chi square test for admission ward, Cuzick non-parametric test for trend for binary variables were used. BMI = body mass index; IMD = index of 
multiple deprivation; MI= myocardial infarction; PVD= peripheral vascular disease; PCI = percutaneous coronary intervention, CABG = coronary 
artery bypass graft, CCU = coronary care unit, ITU = intensive care unit, STEMI = ST elevation myocardial infarction, ACS = acute coronary 
syndrome  
 
 Table 2: Troponin specific unadjusted and adjusted hazards ratios and their corresponding 95% confidence intervals for the risk of 
mortality for people in the older age groups compared to the people in the youngest age group (<65 years) within troponin strata  
 
Troponin I (n=185,510) 
Age 
group 
Unadjusted hazards ratio (95% CI) 
<0.01  0.01-0.049  0.05-0.49  0.5-2.49  2.5-14.99 ≥15.0 All troponin I levels 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 3.49 (2.46-4.97) 2.74 (2.14-3.52) 3.18 (2.92-3.46) 3.17 (2.92-3.45) 3.31 (3.09-3.56) 3.26 (3.05-3.49) 3.23 (3.11-3.35) 
75-84 7.28 (5.20-10.19) 5.42 (4.30-6.84) 6.63 (6.14-7.16) 6.78 (6.29-7.31) 7.60 (7.13-8.11) 7.78 (7.32-8.27) 7.25 (7.01-7.49) 
≥85 19.45 (13.56-
27.91) 
13.07 (10.07-
16.95) 
12.56 (11.62-
13.58) 
13.55 (12.56-
14.62) 
14.36 (13.45-
15.32) 
15.82 (14.86-
16.84) 
14.29 (13.81-14.79) 
 Adjusted hazards ratio (95% CI)*  
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 2.90 (2.04-4.13) 2.25 (1.76-2.89) 2.50 (2.30-2.72) 2.46 (2.27-2.68) 2.64 (2.46-2.84) 2.72 (2.54-2.91) 2.61 (2.51-2.71) 
75-84 5.32 (3.79-7.46) 3.91 (3.10-4.93) 4.43 (4.10-4.79) 4.51 (4.18-4.88) 5.18 (4.84-5.54) 5.50 (5.16-5.87) 4.97 (4.78-5.16) 
≥85 11.70 (8.14-16.81) 8.20 (6.31-10.65) 7.34 (6.76-7.97) 8.19 (7.55-8.87) 8.63 (8.04-9.26) 9.77 (9.12-10.46) 8.59 (8.22-8.97) 
Troponin T (n=134,547) 
Age 
group 
Unadjusted hazards ratio (95% CI) 
<0.01  0.01-0.049 0.05-0.099  0.1-0.49  0.5-1.79  ≥1.8  All troponin T 
levels 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 2.58 (2.16-3.09) 2.87 (2.35-3.50) 2.75 (2.34-3.23) 3.24 (3.02-3.49) 3.20 (2.95-3.48) 3.09 (2.86-3.35) 3.13 (3.00-3.26) 
75-84 6.27 (5.33-7.38) 6.05 (5.06-7.23) 6.03 (5.22-6.97) 6.97 (6.52-7.45) 7.67 (7.11-8.27) 7.43 (6.92-7.97) 7.24 (6.98-7.52) 
≥85 11.84 (9.90-14.17) 10.35 (8.63-12.41) 11.12 (9.63-12.85) 12.89 (12.05-
13.78) 
14.86 (13.77-
16.04) 
15.67 (14.57-
16.85) 
13.96 (13.44-14.49) 
 Adjusted hazards ratio (95% CI)* 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 2.19 (1.83-2.63) 2.26 (1.86-2.76) 2.17 (1.85-2.55) 2.55 (2.36-2.74) 2.52 (2.32-2.75) 2.55 (2.36-2.76) 2.50 (2.39-2.61) 
75-84 4.74 (4.02-5.60) 4.03 (3.37-4.82) 3.96 (3.43-4.58) 4.64 (4.33-4.97) 5.08 (4.70-5.49) 5.19 (4.83-5.58) 4.83 (4.63-5.04) 
≥85 9.24 (7.69-11.11) 6.20 (5.15-7.45) 6.60 (5.69-7.66) 7.69 (7.16-8.26) 8.82 (8.12-9.58) 9.48 (8.78-10.25) 8.27 (7.89-8.66) 
* adjusted for age group, sex, body mass index, current smokers, family history of heart disease, STEMI or non-STEMI, co-
morbidities (hypertension, diabetes, MI, angina, stroke, heart failure, chronic renal failure, peripheral vascular disease), previous PCI, 
previous CABG, serum cholesterol, serum glucose, troponin group, admission medications (aspirin, ACEi, beta-blocker, statin, 
clopidogrel), admission consultant, admission ward. 
 
 Table 3: Unadjusted and adjusted hazards ratios and their corresponding 95% confidence intervals for mortality for higher troponin 
level categories compared to the lowest level of troponin (<0.01 ng/ml) within the same age strata 
Troponin I (n=185,510) Unadjusted hazards ratio (95% CI) 
<65  65-74  75-84 ≥85 All troponin I levels 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.13 (0.79-1.60) 0.88 (0.69-1.14) 0.84 (0.68-1.04) 0.76 (0.58-1.00) 0.92 (0.81-1.05) 
0.05-0.49  1.89 (1.40-2.55) 1.72 (1.40-2.12) 1.72 (1.45-2.05) 1.22 (0.98-1.52) 2.20 (1.98-2.45) 
0.5-2.49  2.16 (1.61-2.91) 1.96 (1.59-2.41) 2.01 (1.69-2.39) 1.59 (1.26-2.02) 2.68 (2.41-2.98) 
2.5-14.99  2.14 (1.59-2.87) 2.03 (1.65-2.49) 2.23 (1.88-2.66) 1.58 (1.27-1.96) 2.72 (2.44-3.02) 
≥15.0 2.10 (1.56-2.81) 1.96 (1.59-2.40) 2.24 (1.88-2.67) 1.71 (1.37-2.12) 2.33 (2.09-2.59) 
 Adjusted hazards ratio (95% CI)* 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.23 (0.86-1.74) 0.95 (0.74-1.23) 0.90 (0.73-1.12) 0.86 (0.65-1.13) 0.94 (0.83-1.07) 
0.05-0.49 1.95 (1.45-1.63) 1.69 (1.37-2.08) 1.63 (1.36-1.94) 1.23 (0.98-1.53) 1.56 (1.40-1.73) 
0.5-2.49 2.22 (1.65-2.99) 1.89 (1.53-2.33) 1.89 (1.58-2.25) 1.64 (1.29-2.08) 1.85 (1.66-2.06) 
2.5-14.99 2.26 (1.69-3.04) 2.06 (1.68-2.54) 2.21 (1.85-2.63) 1.67 (1.34-2.08) 2.05 (1.84-2.28) 
≥15.0 2.41 (1.80-3.24) 2.27 (1.84-2.79) 2.50 (2.09-2.98) 2.01 (1.62-2.52) 2.34 (2.10-2.61) 
Troponin T (n=134,547) Unadjusted hazards ratio (95% CI) 
<65  65-74 75-84 ≥85 All troponin T levels 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.77 (1.43-2.19) 1.97 (1.67-2.32) 1.71 (1.52-1.92) 1.55 (1.34-1.78) 2.32 (2.15-2.49) 
0.05-0.099  2.08 (1.72-2.52) 2.22 (1.91-2.57) 2.00 (1.80-2.23) 1.96 (1.72-2.23) 2.81 (2.63-3.01) 
0.1-0.49 1.95 (1.68-2.27) 2.45 (2.17-2.77) 2.17 (1.98-2.38) 2.45 (2.10-2.85) 2.98 (2.81-3.15) 
0.5-1.79 1.80 (1.55-2.10) 2.24 (1.97-2.54) 2.20 (2.00-2.42) 2.26 (2.00-2.55) 2.78 (2.62-2.95) 
≥1.80 1.87 (1.62-2.18) 2.25 (1.99-2.56) 2.22 (2.02-2.45) 2.49 (2.20-2.81) 2.47 (2.33-2.62) 
 Adjusted hazards ratio (95% CI)* 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.78 (1.44-2.20) 1.83 (1.56-2.16) 1.51 (1.34-1.70) 1.19 (1.03-1.38) 1.49 (1.39-1.61) 
0.05-0.099 2.04 (1.69-2.47) 2.02 (1.74-2.34) 1.71 (1.53-1.90) 1.46 (1.27-1.67) 1.73 (1.61-1.85) 
0.1-0.49  1.92 (1.65-2.23) 2.23 (1.97-2.52) 1.88 (1.71-2.06) 1.83 (1.56-2.14) 1.88 (1.77-1.99) 
0.5-1.79 1.91 (1.64-2.22) 2.19 (1.93-2.49) 2.04 (1.85-2.25) 1.82 (1.60-2.06) 2.03 (1.91-2.16) 
≥1.80 2.19 (1.88-2.54) 2.54 (2.24-2.89) 2.39 (2.17-2.64) 2.24 (1.97-2.55) 2.40 (2.26-2.55) 
* adjusted for age group, sex, body mass index, current smokers, family history of heart disease, STEMI or non-STEMI, comorbidities 
(hypertension, diabetes, MI, angina, stroke, heart failure, chronic renal failure, peripheral vascular disease), previous PCI, previous 
CABG, serum cholesterol, serum glucose, troponin group, admission medications (aspirin, ACEi, beta-blocker, statin, clopidogrel), 
admission consultant, admission ward. 
 
 
 
 
 
 
Supplementary Table 1: Troponin assay specific baseline characteristics of 322,617 men and women of the MINAP acute coronary 
syndrome cohort (2006-2011) according to different troponin categories  
  
Variables† Troponin I cohort (n=186,988) Troponin T cohort (n=135,629) 
<0.01 
(n=2,9
48) 
0.01-
0.049 
(n=6,006
) 
0.05-
0.49 
(n=40,7
30) 
0.5-2.49 
(n=38,3
53) 
2.5-14.99 
(n=49,616
) 
≥15 
(n=49,33
5) 
P-
value‡ 
<0.01 
(n=9,66
1) 
0.01-
0.049 
(n=6,929
) 
0.05-
0.099 
(n=9,37
1) 
0.1-0.49 
(n=43,39
5) 
0.5-
1.79 
(n=32,
720) 
≥1.8 
(n=33,
553) 
P-
value‡ 
Age group 
(years) 
<65 
 
65-74.9 
 
75-84.9 
 
≥85 
 
 
1,402 
(48) 
802 
(27) 
575 
(20) 
169  
(6) 
 
 
2,654 
(44) 
1,640 
(27) 
1,362 
(23) 
350  
(6) 
 
 
13,340 
(33) 
9,919 
(24) 
11,211 
(28) 
6,260 
(15) 
 
 
11,851 
(31) 
9,006 
(23) 
10,975 
(29) 
6,521 
(17) 
 
 
20,166 
(41) 
11,552 
(23) 
11,718 
(24) 
5,899  
(12) 
 
 
22,262 
(40) 
12,884 
(23) 
13,329 
(24) 
6,790 
(12) 
 
 
<0.0001 
 
 
4,550 
(47) 
2,521 
(26) 
1,879 
(19) 
711  
(7) 
 
 
2,139 
(31) 
1,647 
(24) 
2,010 
(29) 
1,133 
(16) 
 
 
2,849 
(30) 
2,152 
(23) 
2,623 
(28) 
1,747 
(19) 
 
 
13,181 
(30) 
9,940 
(23) 
12,479 
(29) 
7,795 
(18) 
 
 
11,001 
(34) 
7,504 
(23) 
8,961 
(27) 
5,254 
(16) 
 
 
13,403 
(40) 
7,763 
(23) 
8,211 
(24) 
4,176 
(12) 
 
 
<0.0001 
Male 
gender 
1,905 
(65) 
3,965 
(66) 
24,841 
(61) 
22,929 
(60) 
31,760 
(64) 
35,061 
(71) 
<0.0001 6,288 
(65) 
4,458 
(64) 
5,909 
(63) 
26,657 
(62) 
20,950
(64) 
23,620 
(71) 
<0.0001 
BMI 
(kg/m
2
) 
28 (6) 28 (6) 28 (6) 27 (6) 27 (6) 27 (6) <0.0001 28 (6) 28 (6) 28 (6) 27 (6) 27 (6) 27 (5) <0.0001 
Current 
smoker 
608 
(22) 
1,193 
(21) 
8,054 
(21) 
8,275 
(23) 
11,797 
(26) 
15,173 
(33) 
<0.0001 2,238 
(24) 
1,422 
(22) 
1,970 
(23) 
9,750 
(24) 
8,476 
(28) 
10,632 
(34) 
<0.0001 
Index of 
multiple 
deprivation 
score 
28 (6) 28 (6) 28 (6) 27 (6) 27 (6) 27 (6) <0.0001 26 (17) 26 (17) 24 (16) 25 (17) 24 (17) 24 (17) <0.0001 
Family 
history of 
heart 
disease 
1,043 
(42) 
2,040 
(45) 
10,297 
(31) 
9,197 
(30) 
12,403 
(31) 
13,563 
(33) 
<0.0001 3,165 
(42) 
1,676 
(33) 
2,341 
(35) 
10,707 
(34) 
8,377 
(35) 
9,057 
(35) 
0.917 
Prior comorbidities 
Hyperlipida
emia 
1,393 
(49) 
2,726 
(49) 
15,014 
(39) 
12,961 
(36) 
16,332 
(35) 
15,172 
(33) 
<0.0001 4,392 
(48) 
2,689 
(41) 
3,213 
(37) 
14,106 
(36) 
9,439 
(32) 
9,099 
(30) 
<0.0001 
Hypertensi
on 
1,612 
(56) 
3,312 
(58) 
21,974 
(56) 
19,736 
(53) 
24,682 
(52) 
22,065 
(47) 
<0.0001 5,158 
(55) 
3,715 
(56) 
4,781 
(54) 
21,942 
(53) 
15,183 
(49) 
14,394 
(46) 
<0.0001 
Diabetes 604 
(21) 
1,271 
(22) 
9,333 
(23) 
8,530 
(23) 
10,220 
(21) 
8,142 
(17) 
<0.0001 1,982 
(21) 
1,675 
(25) 
2,191 
(24) 
9,436 
(22) 
6,189 
(20) 
5,250 
(16) 
<0.0001 
MI 1,092 
(38) 
2,394 
(41) 
14,059 
(36) 
11,613 
(31) 
13,313 
(28) 
9,236 
(19) 
<0.0001 3,516 
(37) 
2,468 
(37) 
3,012 
(34) 
12,808 
(31) 
7,796 
(25) 
5,767 
(18) 
<0.0001 
Angina 1,353 
(47) 
3,121 
(54) 
16,298 
(42) 
13,069 
(35) 
14,695 
(31) 
10,374 
(22) 
<0.0001 4,928 
(52) 
3,063 
(46) 
3,636 
(41) 
14,903 
(37) 
9,195 
(30) 
6,752 
(22) 
<0.0001 
Heart 
failure 
124 (4) 233 (5) 3,085 
(8) 
2,715 
(8) 
3,067 (7) 1,842 (4) <0.0001 341 (4) 606 (9) 816 (9) 3,480 (8) 1,867 
(6) 
1,307 
(4) 
<0.0001 
Stroke 199 (7) 380 (7) 3,906 
(10) 
3,683 
(10) 
4,477 (10) 3,422 (7) <0.0001 755 (8) 735 (11) 947 (11) 4,359 
(11) 
2,769 
(9) 
2,410 
(8) 
<0.0001 
Chronic 
renal failure 
99 (3) 160 (3) 2,462 
(6) 
2,451 
(7) 
2,990 (6) 2,137 (5) <0.0001 210 (2) 369 (6) 616 (7) 2,940 (7) 1,753 
(6) 
1,537 
(5) 
<0.0001 
Peripheral 
vascular 
disease 
106 (3) 201 (4) 1,803 
(5) 
1,885 
(5) 
2,392 (5) 1,828 (4) <0.0001 369 (4) 418 (6) 505 (6) 2,317 (6) 1,507 
(5) 
1,286 
(4) 
<0.0001 
Prior interventions 
PCI 675 
(24) 
1,352 
(24) 
5,678 
(15) 
3,830 
(10) 
4,205 (9) 3,215 (7) <0.0001 2,151 
(23) 
976 (15) 1,051 
(12) 
3,886 
(10) 
2,254 
(8) 
2,050 
(7) 
<0.0001 
CABG 300 
(11) 
711 (13) 3,832 
(10) 
2,921 
(8) 
3,185 (7) 1,969 (4) <0.0001 1,162 
(12) 
654 (10) 788 (9) 3,198 (8) 1,741 
(6) 
1,107 
(4) 
<0.0001 
Biochemical results 
Serum 
cholesterol 
(mmol/L) 
3.9 
(2.1) 
4.6 (1.3) 4.5 (1.6) 4.6 (1.6) 4.7 (1.6) 4.9 (1.5) <0.0001 4.4 (1.8) 4.5 (1.6) 4.5 (1.7) 4.6 (1.7) 4.7 
(1.6) 
4.9 
(1.5) 
<0.0001 
Serum 
glucose 
(mmol/L) 
7.5 
(5.0) 
7.2 (3.6) 7.8 (4.2) 8.2 (4.5) 8.4 (4.8) 8.7 (4.8) <0.0001 7.2 (3.7) 7.7 (4.3) 8.1 (5.1) 8.4 (5.7) 8.6 
(5.6) 
8.9 
(5.3) 
<0.0001 
Admission medications 
ACE 
inhibitor 
1,175 
(48) 
2,455 
(49) 
16,387 
(45) 
14,213 
(41) 
17,070 
(38) 
13,328 
(30) 
<0.0001 4,237 
(46) 
3,113 
(49) 
3,672 
(43) 
16,099 
(41) 
10,407 
(36) 
8,892 
(30) 
<0.0001 
Beta 
blocker 
1,198 
(49) 
2,414 
(48) 
13,495 
(37) 
11,184 
(33) 
13,322 
(30) 
10,920 
(25) 
<0.0001 4,014 
(44) 
2,443 
(38) 
2,866 
(34) 
12,776 
(33) 
8,576 
(30) 
7,428 
(25) 
<0.0001 
Statin 1,593 
(65) 
3,447 
(65) 
20,137 
(54) 
17,215 
(49) 
20,054 
(44) 
15,703 
(35) 
<0.0001 5,701 
(62) 
3,726 
(57) 
4,453 
(51) 
19,545 
(49) 
12,665
(43) 
10,749 
(35) 
<0.0001 
Clopidogrel 387 
(26) 
808 (28) 4,301 
(23) 
3,632 
(18) 
4,462 (16) 3,497 
(13) 
<0.0001 1,830 
(26) 
850 (23) 981 (20) 5,590 
(22) 
3,641 
(19) 
2,810 
(15) 
<0.0001 
Aspirin 1,673 
(57) 
3,969 
(66) 
22,421 
(55) 
20,265 
(53) 
27,192 
(55) 
30,207 
(61) 
<0.0001 6,151 
(64) 
4,240 
(61) 
5,257 
(56) 
23,331 
(54) 
18,007 
(55) 
20,444 
(61) 
<0.0001 
Management, setting and diagnosis 
Cardiologis
t as lead 
consultant 
1,074 
(37) 
3,133 
(53) 
14,908 
(37) 
13,523 
(36) 
20,284 
(41) 
27,302 
(56) 
<0.0001 4,702 
(49) 
3,714 
(54) 
5,681 
(62) 
25,636 
(60) 
17,136
(53) 
13,302 
(40) 
<0.0001 
Admission 
ward 
CCU 
 
ITU  
Cardiac 
ward  
Other 
 
 
1,079 
(39) 
13(<1) 
570 
(21) 
1,075 
(39) 
 
 
2,190 
(39) 
7 (<1) 
441 (8) 
 
3,023 
(53) 
 
 
13,987 
(37) 
254 (1) 
4,218 
(11) 
18,957 
(51) 
 
 
13,579 
(38) 
487 (1) 
3,604 
(10) 
17,639 
(50) 
 
 
22,628 
(49) 
783 (2) 
3,996 (9) 
 
18,818 
(41) 
 
 
32,614 
(69) 
976 (2) 
2,986 (6) 
 
10,421 
(22) 
 
<0.0001 
 
 
5,361 
(58) 
34 (<1) 
638 (7) 
 
3,241 
(35) 
 
 
2,956 
(48) 
29 (<1) 
603 (10) 
 
2,633 
(42) 
 
 
3,638 
(43) 
85 (1) 
928 (11) 
 
3,788 
(45) 
 
 
 18,506 
(47) 
547 (1) 
3,700 (9) 
 
16,794 
(42) 
 
 
18,095 
(59) 
571 (2) 
2,005 
(7) 
9,898 
(32) 
 
 
25,243 
(78) 
656 (2) 
1,199 
(4) 
5,214 
(16) 
 
<0.0001 
Diagnosis  
STEMI 
 
ACS but 
not STEMI 
 
537 
(18) 
2,411 
(82) 
 
621  
(10) 
5,385 
(90) 
 
4,646 
(11) 
36,084 
(89) 
 
5,987 
(16) 
32,366 
(84) 
 
14,021 
(28) 
35,595 
(72) 
 
32,216 
(65) 
17,119 
(65) 
 
<0.0001 
 
1,833 
(19) 
7,828 
(81) 
 
986 
(14) 
5,943 
(86) 
 
1,374 
(15) 
7,997 
(85) 
 
7,854 
(18) 
35,541 
(82) 
 
12,148 
(37) 
20,572 
(63) 
 
24,142 
(72) 
24,142 
(72) 
 
<0.0001 
Discharge medications 
ACE 
inhibitor 
1,632 
(72) 
3,589 
(73) 
24,859 
(70) 
23,792 
(71) 
31,663 
(73) 
33,914 
(77) 
<0.0001 5,748 
(69) 
4,243 
(68) 
5,447 
(66) 
26,197 
(69) 
20,648
(72) 
22,853 
(77) 
<0.0001 
Beta 
blocker 
1,772 
(72) 
3,783 
(72) 
24,159 
(67) 
22,705 
(67) 
30,327 
(69) 
32,459 
(74) 
<0.0001 5,782 
(68) 
3,992 
(63) 
5,199 
(62) 
24,955 
(65) 
19,759 
(69) 
21,603 
(72) 
0.008 
Statin 2,182 
(87) 
4,664 
(87) 
29,881 
(82) 
27,717 
(82) 
36,078 
(82) 
37,097 
(84) 
<0.0001 7,556 
(86) 
5,064 
(80) 
6,618 
(78) 
31,101 
(80) 
23,714 
(82) 
25,137 
(84) 
<0.0001 
Clopidogrel 853 
(73) 
1,745 
(67) 
13,127 
(75) 
14,246 
(79) 
19,698 
(80) 
19,691 
(80) 
<0.0001 3,611 
(58) 
2,095 
(64) 
3,134 
(68) 
17,342 
(72) 
13,476 
(73) 
13,316 
(74) 
<0.0001 
Aspirin 2,127 
(84) 
4,570 
(85) 
29,577 
(81) 
27,518 
(80) 
25,835 
(81) 
36,790 
(83) 
0.280 7,426 
(84) 
5,033 
(78) 
6,586 
(77) 
30,937 
(79) 
23,607 
(81) 
25,034 
(83) 
0.049 
Outcome 
Death at 
follow up   
367 
(12) 
680  
(11) 
9,611 
(24) 
10,896 
(28) 
14,378 
(29) 
12,431 
(25) 
0.586 1,330 
(14) 
1,746 
(25) 
2,780 
(30) 
14,052 
(32) 
10,117 
(31) 
9,147 
(27) 
<0.0001 
†Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  ‡ Spearman correlation test for 
continuous variables and age group, Chi square test for Admission ward and Cuzick non-parametric test for trend for binary variables 
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Supplementary Table 2: Comparison of baseline characteristics of the included and excluded cohort 
 
Variables and associations with 
missing troponin I 
Odds ratio (95% CI) p-value 
Age 0.9989731 (0.9984244-0.9995221) <0.001 
Sex 1.043736 (1.028532-1.059165) <0.001 
Prior MI 0.9011443 (0.8858318-0.9167216) <0.001 
Prior PCI 1.006812 (0.9828668-1.031341) 0.580 
Prior CABG 0.9471632 (0.9205756-0.9745187) <0.001 
Diabetes 0.9706904 (0.9539319-0.9877433) 0.001 
Hypertension 0.9254187 (0.9125855-0.9384322) <0.001 
Current smoker 0.9133879 (0.8983817-0.9286448) <0.001 
 
Variables and associations with 
missing troponin T 
Odds ratio (95% CI) p-value 
Age 0.9961729 (0.9956016-0.9967446) <0.001 
Sex 0.9989445 (0.9838167-1.014305) 0.892 
Prior MI 1.006932 (0.9891724-1.02501) 0.447 
Prior PCI 1.036507 (1.010787-1.062881) 0.005 
Prior CABG 0.9469983 (0.9195531-0.9752626) <0.001 
Diabetes 0.9837969 (0.9661617-1.001754) 0.077 
Hypertension 1.025531 (1.010734-1.040545) 0.001 
Current smoker 1.049961 (1.03199-1.068244) <0.001 
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Figure 1: Adjusted hazards ratios (95% confidence intervals) of mortality according to 
various age groups within troponin strata 
  34 
Figure 2: Adjusted hazard ratios (95% confidence intervals) of mortality according to various 
levels of peak troponin categories within age strata 
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Supplementary Figure 1: Crude mortality rates (95% confidence intervals) at follow up 
(August 2011) in different age groups by peak troponin categories 
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Supplementary Figure 2: Crude mortality rates (95% confidence intervals) compared to 
expected mortality of similar age categories at follow up (August 2011) for the oldest and 
youngest age groups by peak troponin categories  
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Data Supplement 1: MINAP definitions of variables 
 
Variable Definition 
Chronic renal failure Creatinine chronically >200 micromol/L 
Cerebrovascular disease A history of cerebrovascular ischaemia. To include transient 
cerebral ischaemic episodes as well as events with deficit 
lasting >24 hours. 
Peripheral vascular 
disease 
The presence of peripheral vascular disease, either presently 
symptomatic or previously treated by intervention or surgery. 
Includes known renovascular disease and aortic aneurysm. 
Chronic obstructive 
pulmonary disease 
Any form of obstructive airways disease. 
Congestive cardiac failure A previously validated diagnosis of heart failure on any 
therapeutic regime. 
Smoking Ex-smoker or current smoker 
Known diabetes mellitus Diabetic with any of dietary control, receiving insulin or oral 
medication. 
Hypertension A patient already receiving treatment (drug, dietary or 
lifestyle) for hypertension or with recorded  BP > 140/90 on at 
least two occasions prior to admission. 
The MINAP dataset and definitions are freely accessible at: 
http://www.ucl.ac.uk/nicor/audits/minap/dataset 
 
